# Research Program: Cancer Immunology

> **NIH NIH P30** · FRED HUTCHINSON CANCER RESEARCH CENTER · 2020 · $102,848

## Abstract

PROJECT SUMMARY: CANCER IMMUNOLOGY (CI) 
Over the past decade, immunotherapy has emerged as an established modality that is revolutionizing the 
treatment of many cancers. The Cancer Immunology (CI) Research Program has focused on genetically 
manipulating T cells, applying new principles of synthetic biology, and combining engineered T cells with small 
molecules and antibodies to broaden the applications and improve the safety and efficacy of adoptive 
immunotherapy. Despite the success achieved with immunologic approaches in treating some malignancies, 
major gaps exist in our current understanding of the complex relationship between progressing tumors and 
host immunity, and these must be understood and overcome to achieve the potential of immunotherapy in 
many common cancers. The CI program will focus on systematically tackling these barriers to eradicating 
tumors using a variety of immunotherapeutic modalitie alone and in combination. The specific aims of CI are 
(1) to develop effective and safe cellular immunotherapies for adult and pediatric hematologic malignancies 
and solid tumors, (2) to identify and overcome the barriers to immune-mediated tumor eradication using clinical 
specimens and preclinical models, (3) to translate discoveries in basic immunology and synthetic biology to 
novel clinical applications in cancer immunotherapy. 
The Cancer Immunology (CI) program currently has 39 members from 11 departments and divisions and 4 
Consortium institutions. Nineteen members have primary appointments at Fred Hutch, 12 members at 
University of Washington, and 8 members at Seattle Children’s. Fourteen new faculty members joined this 
program in the last cycle. The current research support of CI members is $23.4M (direct costs) in research 
grant funding, of which $4.4M (19%) is from the NCI and $7.8M (33%) is peer reviewed. The Cancer 
Immunology program published a total of 470 papers in the last grant period, of which 14% were intra- 
programmatic, 49% were inter-programmatic, and 50% had external co-authors. Program members have 
utilized all 12 of the Consortium Shared Resources. This P30 grant also assists this program by providing 
administrative and logistical support for CI meetings, pilot funding for new research projects, and recruitment 
resources for new faculty.

## Key facts

- **NIH application ID:** 9853663
- **Project number:** 2P30CA015704-45
- **Recipient organization:** FRED HUTCHINSON CANCER RESEARCH CENTER
- **Principal Investigator:** Cameron John Turtle
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $102,848
- **Award type:** 2
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9853663

## Citation

> US National Institutes of Health, RePORTER application 9853663, Research Program: Cancer Immunology (2P30CA015704-45). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9853663. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*